MX2012004922A - Compuesto de 5,6-dihidro-1h-piridin-2-ona deuterados. - Google Patents

Compuesto de 5,6-dihidro-1h-piridin-2-ona deuterados.

Info

Publication number
MX2012004922A
MX2012004922A MX2012004922A MX2012004922A MX2012004922A MX 2012004922 A MX2012004922 A MX 2012004922A MX 2012004922 A MX2012004922 A MX 2012004922A MX 2012004922 A MX2012004922 A MX 2012004922A MX 2012004922 A MX2012004922 A MX 2012004922A
Authority
MX
Mexico
Prior art keywords
compounds
deuterated
pyridin
dihydro
hepatitis
Prior art date
Application number
MX2012004922A
Other languages
English (en)
Inventor
Stephen E Webber
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of MX2012004922A publication Critical patent/MX2012004922A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está dirigida a compuestos de 5,6-dihidro-1H-piridin-2-ona deuterados y composiciones farmacéuticas que contienen tales compuestos que son útiles en el tratamiento de las infecciones provocadas por el virus de la Hepatitis C.
MX2012004922A 2009-10-28 2010-10-27 Compuesto de 5,6-dihidro-1h-piridin-2-ona deuterados. MX2012004922A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25572809P 2009-10-28 2009-10-28
PCT/US2010/054276 WO2011056647A1 (en) 2009-10-28 2010-10-27 Deuterated 5,6-dihydro-1h-pyridin-2-one compounds

Publications (1)

Publication Number Publication Date
MX2012004922A true MX2012004922A (es) 2012-05-29

Family

ID=43970270

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004922A MX2012004922A (es) 2009-10-28 2010-10-27 Compuesto de 5,6-dihidro-1h-piridin-2-ona deuterados.

Country Status (10)

Country Link
US (1) US8586578B2 (es)
EP (1) EP2493476A4 (es)
JP (1) JP2013509420A (es)
KR (1) KR20120092142A (es)
CN (1) CN102858344A (es)
BR (1) BR112012009796A2 (es)
CA (1) CA2778907A1 (es)
MX (1) MX2012004922A (es)
RU (1) RU2012121847A (es)
WO (1) WO2011056647A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2897347A1 (en) * 2013-01-14 2014-07-17 F. Hoffmann-La Roche Ag A novel process for the preparation of n-(4-nitro-2-sulfamoyl-phenyl)-malonamic acid methyl ester and n-(4-amino-2-sulfamoyl-phenyl)-malonamic acid methyl ester

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
BR9507200A (pt) 1994-03-25 1997-09-16 Isotechnika Inc Melhora da eficácia de drogas por deuteração
DE60001623T2 (de) * 1999-12-03 2003-12-18 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
US20040034041A1 (en) 2000-05-10 2004-02-19 Dashyant Dhanak Novel anti-infectives
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
WO2003059356A2 (en) 2001-10-30 2003-07-24 Smithkline Beecham Corporation Novel anti-infectives
US20050075331A1 (en) 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
EP1786807B1 (en) 2004-08-23 2009-07-29 F.Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CA2589527A1 (en) 2004-12-17 2006-06-22 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
WO2006093801A1 (en) 2005-02-25 2006-09-08 Abbott Laboratories Thiadiazine derivatives useful as anti-infective agents
RU2007143049A (ru) 2005-04-21 2009-05-27 Ниппон Синяку Ко., Лтд. (Jp) Производное фталазинона и содержащая его фармацевтическая композиция
CN101189230A (zh) 2005-05-04 2008-05-28 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物
WO2007041630A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
WO2007109459A2 (en) 2006-03-21 2007-09-27 Janssen Pharmaceutica, Nv Pyridines and pyridine n-oxides as modulators of thrombin
US20080090814A1 (en) 2006-06-22 2008-04-17 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
EP2038286B1 (en) * 2006-06-22 2017-03-08 Anadys Pharmaceuticals, Inc. Pyrro[1,2-b]pyridazinone compounds
CL2007003587A1 (es) * 2006-12-12 2008-07-04 Anadys Pharmaceuticals Inc Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c.
WO2008073987A1 (en) 2006-12-12 2008-06-19 Anadys Pharmaceuticals, Inc. Saturated fused [1,2-b] pyridazinone compounds
US20080188466A1 (en) 2006-12-21 2008-08-07 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
US20080275032A1 (en) 2006-12-29 2008-11-06 Yuefen Zhou Pyridazinone compounds
US20080227774A1 (en) 2007-03-15 2008-09-18 Frank Ruebsam 5,5-disubstituted-indolizinone compounds
UA100120C2 (en) * 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
US7834009B2 (en) 2007-08-27 2010-11-16 Anadys Pharmaceuticals, Inc. 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds

Also Published As

Publication number Publication date
CN102858344A (zh) 2013-01-02
EP2493476A1 (en) 2012-09-05
US8586578B2 (en) 2013-11-19
US20120283251A1 (en) 2012-11-08
BR112012009796A2 (pt) 2020-08-18
EP2493476A4 (en) 2013-06-19
CA2778907A1 (en) 2011-05-12
RU2012121847A (ru) 2013-12-10
JP2013509420A (ja) 2013-03-14
WO2011056647A1 (en) 2011-05-12
KR20120092142A (ko) 2012-08-20

Similar Documents

Publication Publication Date Title
TN2009000398A1 (en) 5,6-dihydro-1h-pyridin-2-one compounds
EA201390538A1 (ru) Противовирусные соединения
TW200635596A (en) Pyridazinone compounds
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
MY152971A (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
HK1166788A1 (es)
MX2010008531A (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
HK1123733A1 (en) Viral hepatitis treatment
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX337936B (es) Compuestos inhibidores del virus de la hepatitis c.
ATE551337T1 (de) Inhibitoren des hepatitis-c-virus
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
MY170941A (en) Pyrimidine derivatives for the treatment of viral infections
IN2012DN01855A (es)
WO2013074386A3 (en) Hcv ns3 protease inhibitors
EA201400537A1 (ru) 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА
WO2007150001A8 (en) Pyrro[1,2-b]pyridazinone compounds
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds
MX2015011193A (es) Compuestos antivirales.
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي

Legal Events

Date Code Title Description
FA Abandonment or withdrawal